Document:

Exhibit 10.3

EXHIBIT 10.3

LICENSE AGREEMENT

THIS AGREEMENT is made as of the 24th day of April, 2009 (the “Effective Date”)

BETWEEN

	 	 	 
	HearUSA, INC.,

a corporation established under the laws of Delaware.

1250 Northpoint Parkway, West Palm Beach, FL 33407

	Telephone Number:

	 	(561) 478-8770 ext. 133
	Fax Number:

	 	(561) 688-8893

(hereinafter, “Licensor”)

AND

	 	 	 
	HELIX HEARING CARE OF AMERICA CORP.,

a corporation established under the laws of Canada

815 Taylor Creek Drive, Suite 203, Cumberland, ON K1C 1T1

	Telephone Number:

	 	(613) 824-2771
	Fax Number:

	 	(613) 824-1109

(hereinafter, “Licensee”)

IN CONSIDERATION of the covenants and agreements set out in this Agreement, and other good and
valuable consideration, the parties agree as follows:

1. BACKGROUND AND DEFINITIONS

1.1 Definitions. A glossary of defined terms is set out in Schedule A (Glossary). All capitalized
terms used in this License Agreement will have the meaning set out in Schedule A.

1.2 Background. Licensee wishes to license the Software. Licensor is engaged in a business
substantially similar to that carried on by the Licensee and operates and maintains the Software in
support of its business.

2. LICENSE

2.1 Grant. Licensor grants to Licensee a perpetual, non-transferable (except as set forth in
Section 11.4), irrevocable (subject to the provisions in Section 4) license as follows with respect
to the Software and Documentation:

	 	(a)	 	to use the Software in connection with Licensee’s operations, for the benefit
of Licensee, in accordance with the terms of this Agreement, including: (i) use for
disaster recovery, training, testing and production purposes; and (ii) running,
executing, storing, transmitting, copying and networking the Software;

	 	(b)	 	to reproduce copies of applicable Documentation as required by Licensee;

	 	(c)	 	to duplicate the Software for archival or back-up purposes and store such
duplicate copies at locations other than Licensee’s location set out at the start of
this Agreement provided that: (i) the copy contains all of the original Software’s
proprietary notices; (ii) Licensee maintains accurate and up-to-date records of the
location of any copy made; and (iii) Licensee agrees not to transfer any back-up copy
of the Software unless in accordance with the assignment provisions of this Agreement;

 

 

 

	 	(d)	 	to use the Software at an alternative processing site concurrent with use in
the primary processing location for disaster recovery purposes, as well as for disaster
recovery testing and drills; and

	 	(e)	 	to create interfaces between the Software and other systems and program
materials as may be required by Licensee to achieve the maximum benefits from its use
of the Software and of such other systems and program materials.

Furthermore, Licensee may sublicense the Software and Documentation to Licensor or any of its
Affiliates for use in Canada.

2.2 Reserved Rights. Except for the limited license rights expressly granted in this Agreement,
Licensor reserves all rights, title and interest in and to the Software and Documentation.

2.3 Exclusivity. Subject to the terms and conditions of this Agreement, the license granted in
Section 2.1 is an exclusive license in all provinces and territories in Canada. During any period
of time that Licensor is obligated to provide any services to Licensee in respect of the Software,
Licensor may use the Software in all provinces and territories in Canada for the sole purpose of
providing such services to Licensee.

2.4 Restrictions. Licensee agrees not to (and will not allow, direct or authorize any User to):
(i) use the Software other than in accordance with this Agreement; (ii) remove any proprietary
notices from the Software or Documentation; (iii) sublicense, sell or otherwise distribute the
Software to any third party, except, Licensee shall be entitled to permit any service providers to
Licensee to exercise the rights and licenses granted under this Agreement only for the purposes of
providing services to Licensee, as the case may be; or (iv) unless otherwise expressly agreed in
writing by Licensee and Licensor:

	 	(a)	 	decompile, disassemble, or reverse engineer the Software; or

	 	(b)	 	modify or create any derivative works based on the Software.

2.5 Alternative Licenses. Licensor agrees that this Agreement is the only agreement between the
parties with respect to the Software and Documentation and that any shrink wrap or click wrap
license terms included or presented with either is not binding on the parties.

2.6 Modifications. Licensor shall not be required under this Agreement to: (i) provide
Enhancements, Updates or error corrections, or (ii) create any interfaces, program materials, or
other derivative works or modifications for the benefit of Licensee.

3. FEES AND PAYMENT

3.1 Fees. The fee payable by Licensee to Licensor applicable to Licensee’s use of the Software and
Documentation (“Fees”) is the lump sum amount of $5,000,000 Canadian which amount Licensor
acknowledges having received as of the date hereof.

3.2 Taxes. None of the Fees are subject to any taxes whatsoever.

3.3 Canadian Currency. All amounts specified in this Agreement refer to Canadian currency.

4. TERMINATION

4.1 Termination by Licensee. Licensee may terminate this Agreement immediately on written notice
to Licensor, if Licensor is in material default of any provision of this Agreement that is not
cured or addressed to the satisfaction of Licensee (acting reasonably) within 20 Business Days
following written notice of the default from Licensee.

4.2 Termination by Licensor. Licensor may terminate this Agreement immediately on written notice
to Licensee, if Licensee is in material default of any provision of this Agreement that is not
cured or addressed to the
satisfaction of Licensor (acting reasonably) within 20 Business Days following written notice of
the default from Licensor.

			
	 
	 	 
	License Agreement — CMS Software
	 	Confidential

 

2

 

4.3 Termination and Licenses. If Licensor exercises its termination rights pursuant to Section 4.2
of this Agreement, all licenses granted under Section 2 are terminated immediately and Licensee
will cease all use of the affected Software, and shall return, delete or destroy all copies of the
Software and Documentation. Notwithstanding the foregoing, Licensee may retain one archival copy
of the Software and the Documentation.

4.4 Software No Longer Used By Licensor. If, at any time after 36 months from the Effective Date,
Licensor provides to Licensee a written notice that Licensor has permanently ceased its use of the
Software outside of Canada, Licensee will, within 180 days of its receipt of such written notice,
cease its use of the Software.

4.5 Termination for Convenience by Licensee. If, pursuant to Section 11.4, Licensor assigns its
rights or delegates its duties under this Agreement, either in whole or in part, Licensee may, in
its sole discretion, terminate this Agreement upon written notice to Licensor. In the event of
such termination under this Section 4.5 neither Licensor nor its assignee will have any further
obligations or liabilities under this Agreement except pursuant to those provisions of this
Agreement that survive termination of this Agreement pursuant to Section 4.7.

4.6 Intellectual Property Infringement Claim. If Licensor provides to Licensee a written legal
opinion from its legal counsel (whose legal practice is principally in the intellectual property
law field) that Licensee’s or Licensee’s Representatives continued use of the Software will likely
result in an infringement of a third party’s Intellectual Property Rights in or to the Software,
Licensee will cease its use of the Software within 30 days of Licensee’s receipt of such written
legal opinion.

4.7 Survival. Those Sections which by their nature should survive the termination of this
Agreement will survive termination, including Sections 1.1, 2.2, 4.3, 4.4, 4.6, 4.7, 5, 6.4, 7, 8,
9, 10 and 11.

5. CONFIDENTIAL INFORMATION

5.1 General. Licensee and Licensor agree to be bound by the terms and conditions set out in
Schedule C, and any additional terms and conditions regarding privacy, confidentiality or security
set out in this Agreement.

6. WARRANTIES AND DISCLAIMERS OF WARRANTIES

6.1 Right to Grant Licenses. Licensor represents and warrants to and covenants with Licensee,
which representations, warranties and covenants will continue for a period of 24 months after the
Effective Date, as follows: (i) Licensor has the right and authority to grant the rights and
licenses set out in this Agreement free of any security interest, lien, encumbrance or claim of any
kind in favour of or by any third party; and (ii) neither the Software nor the Documentation will
infringe upon or violate any third-party Intellectual Property Rights.

6.2 Exclusion. The warranties set out in Section 6.1 do not extend to any damages, malfunctions,
or non-conformities caused by: (i) Licensee’s use of the Software in violation of the license
granted under this Agreement; or (ii) the Software having been modified other than by Licensor.

6.3 Authority. Licensor represents and warrants to and covenants with Licensee that Licensor has
the right and authority to enter into this Agreement. Licensee represents and warrants to and
covenants with Licensor that Licensee has the right and authority to enter into this Agreement.

6.4 Disclaimer. THE SOFTWARE IS PROVIDED BY THE LICENSOR TO THE LICENSEE “AS-IS” AND, WITH THE
EXCEPTION OF THE EXPRESS REPRESENTATIONS, WARRANTIES AND COVENANTS CONTAINED IN SECTION 6.1 AND
SECTION 6.3, LICENSOR EXPRESSLY DISCLAIMS ANY OTHER REPRESENTATIONS, WARRANTIES, COVENANTS OR
CONDITIONS WITH RESPECT TO THE SOFTWARE, DOCUMENTATION, OR OTHERWISE ARISING FROM THIS AGREEMENT
WHETHER EXPRESS OR IMPLIED, PAST OR PRESENT, STATUTORY OR OTHERWISE, INCLUDING ANY IMPLIED
WARRANTIES OR CONDITIONS OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. WITH THE
EXCEPTION OF ANY EXPRESS REPRESENTATIONS, WARRANTIES AND COVENANTS CONTAINED IN THIS AGREEMENT,
LICENSEE EXPRESSLY DISCLAIMS ANY OTHER
REPRESENTATIONS, WARRANTIES, COVENANTS OR CONDITIONS ARISING FROM THIS AGREEMENT WHETHER EXPRESS OR
IMPLIED, PAST OR PRESENT, STATUTORY OR OTHERWISE.

			
	 
	 	 
	License Agreement — CMS Software
	 	Confidential

 

3

 

7. INDEMNIFICATION

7.1 Intellectual Property Indemnification. Licensor will indemnify and hold Licensee and
Licensee’s Representatives harmless from any and all charges, losses, damages and expenses
(including legal fees and expenses) incurred in connection with any claims, demands, suits,
actions, and other liabilities asserted against any of them as a result of alleged or actual
infringement of any Intellectual Property Right arising from the receipt or use of the Software or
Documentation by Licensee, Licensee’s Representatives or Users, provided that Licensee: (i) gives
Licensor prompt written notice of any such claim; (ii) gives Licensor all reasonable co-operation,
information and assistance to handle the defense or settlement; (iii) gives Licensor, immediately
upon Licensor’s request, sole control of the defense and settlement negotiations; and (iv) except
to the extent required by law, Licensee makes no admission regarding any such claim without
Licensor’s prior written consent. Licensor may not agree to any settlement of any claim that
results in any obligations being incurred by Licensee, Licensee’s Representatives or Users without
Licensee’s prior written consent. Provided that Licensor complies with this Section 7, Licensee
shall have no remedy against Licensor in addition to the indemnification provided above, except it
may at its option terminate this Agreement.

7.2 Harmful Code Indemnification. Licensor will indemnify and hold Licensee harmless from any and
all losses, damages and expenses incurred in connection with any harmful or hidden programs or data
incorporated in the Software with malicious and mischievous intent including viruses, time bombs,
trap doors or similar malicious instructions, techniques or devices capable of disrupting,
disabling, damaging or shutting down a computer system or software or hardware component thereof
(“Harmful Code”). Once Licensee has actual knowledge of any Harmful Code, Licensee will use
commercially reasonable efforts to mitigate any of its potential losses, damages and expenses. The
indemnity set out this Section 7.2 shall be subject to the limitation of liability set out in
Section 8.1, Section 8.2 and Section 8.3 and shall terminate 3 years from the Effective Date.

8. LIMITATION OF LIABILITY

8.1 Indirect Damages. NEITHER PARTY (INCLUDING ITS REPRESENTATIVES) WILL BE LIABLE TO THE OTHER IN
ANY WAY WHATSOEVER, FOR ANY INDIRECT, PUNITIVE, INCIDENTAL, OR SPECIAL DAMAGES. THIS LIMITATION
WILL APPLY WHETHER OR NOT THE DAMAGES ARE FORESEEABLE OR THE DEFAULTING PARTY HAS BEEN ADVISED OF
THE POSSIBILITY OF SUCH DAMAGES.

8.2 Direct Damages. THE PARTIES AGREE THAT THE MAXIMUM AGGREGATE LIABILITY OF EACH PARTY FOR ANY
CLAIM, ACTION OR DEMAND ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT (“CLAIM”) WILL BE
LIMITED TO SUCH DIRECT DAMAGES AS ARE ACTUALLY INCURRED BY THE CLAIMING PARTY.

8.3 Limit. IN NO EVENT WILL THE TOTAL CUMULATIVE LIABILITY OF LICENSOR (INCLUDING ITS
REPRESENTATIVES) TO LICENSEE (INCLUDING ITS REPRESENTATIVES), FOR ANY CLAIMS ARISING OUT OF OR
RELATING TO THIS AGREEMENT, EXCEED $500,000.00.

8.4 Exceptions. THE EXCLUSIONS AND LIMITATIONS OF LIABILITY SET OUT IN SECTION 8.1, SECTION 8.2
AND SECTION 8.3 DO NOT APPLY TO ANY CLAIM ARISING FROM FRAUD OR WILFUL MISCONDUCT OR ANY CLAIM FOR
INDEMNIFICATION UNDER SECTION 7.1. OTHERWISE, THE FOREGOING PROVISIONS SET OUT IN THIS SECTION 8
WILL APPLY REGARDLESS OF THE FORM OR CAUSE OF ACTION.

9. DISPUTE RESOLUTION

9.1 General. The Parties agree to use the dispute resolution procedures set out in Schedule D to
resolve any disputes which may arise out of or in connection with this Agreement or which are
otherwise related to this Agreement.

			
	 
	 	 
	License Agreement — CMS Software
	 	Confidential

 

4

 

9.2 Exceptions. Notwithstanding Section 9.1, the parties acknowledge and agree that either party
shall be entitled to seek an injunction or other equitable relief in order to prevent any
continuing or ongoing breach of this Agreement, or any violation of any other legal obligation of
the other party with respect to any Confidential Information or Personal Information required to be
protected under this Agreement.

10. NOTICE

10.1 Notices. Any notice given pursuant to this Agreement will be in writing and addressed to the
other party at the address for the other party listed at the start of this Agreement. Any such
notice will be deemed to have been received two Business Days following: (i) deposit with a
globally recognized overnight delivery service, all delivery charges pre-paid; or (ii) transmission
if sent by facsimile and receipt confirmed by the facsimile machine used. Either party may
designate a different address by written notice to the other party given in accordance with this
Section.

11. GENERAL

11.1 Entire Agreement. This Agreement constitutes the complete and exclusive agreement between the
parties with respect to its subject matter, and supersedes and replaces any and all prior or
contemporaneous discussions, negotiations, understandings and agreements, written and oral,
regarding its subject matter. Except as expressly set out in this Agreement, this Agreement may be
changed only by a written document signed by authorized representatives of Licensor and an
authorized representative of Licensee. Should any provision of this Agreement be held to be
invalid by a court of competent jurisdiction, then that provision will be enforced to the extent
permissible, and all other provisions will remain in effect and are enforceable by the parties.

11.2 Interpretation.

	 	(a)	 	The headings used in this Agreement are for convenience of reference only, and
are not intended to be full or accurate descriptions of the content of the paragraphs.

	 	(b)	 	No provision of this Agreement will be interpreted against any party merely
because that party or its legal representative drafted the provision.

	 	(c)	 	This Agreement has been drawn up in English at the request of the parties.

	 	(d)	 	All remedies are cumulative.

	 	(e)	 	This Agreement is for the benefit of, and binding upon the parties, their
successors and permitted assigns.

	 	(f)	 	Throughout this Agreement, the term “including” or the phrases “e.g.,” or “for
example” have been used to mean “including, without limitation”. The examples provided
should not be considered to be all-inclusive.

	 	(g)	 	Words denoting the singular include the plural and vice versa, and words
denoting any gender include all genders.

	 	(h)	 	Except as otherwise provided, the terms “hereunder”, “herein”, “hereby”,
“hereof”, “hereto”, “hereinafter” and any other similar expression when used in this
Agreement usually refer to this Agreement as a whole rather than to any particular
section thereof.

11.3 Waiver. No term of this Agreement will be deemed to be waived by reason of any previous
failure to enforce it. No term of this Agreement may be waived except in a writing signed by the
party waiving enforcement.

			
	 
	 	 
	License Agreement — CMS Software
	 	Confidential

 

5

 

11.4 Assignment. Except as expressly set out in this Agreement or unless the context otherwise
requires, neither party may assign its rights or delegate its duties under this Agreement, either
in whole or in part, without the prior written consent of the other party, such consent not to be
unreasonably withheld or delayed. Notwithstanding the preceding sentence, either party may, without
the prior written consent of the other party, assign this Agreement as
part of a sale of all or substantially all of its assets; provided that the assigning party gives
the other party written notice of such assignment on the date the assignment is made.
Notwithstanding the foregoing, Licensor shall not be entitled to assign, either in whole or in
part, any of its rights or delegate any of its duties under this Agreement to any third party
(including any Affiliate) who is in the business of operating hearing clinics or hearing centres in
Canada. As part of any assignment by Licensor, as permitted pursuant to this section 11.4,
Licensor shall obtain written assurances from its assignee that such assignee does not and shall
not operate any hearing clinics or hearing centres in Canada. Upon any assignment hereunder, the
assigning party shall remain responsible for the acts and omissions of its assignee. Subject to
the restrictions in this Section 11.4, this Agreement will be binding on, will inure to the benefit
of, and will be enforceable against the parties and their respective successors and assigns.

11.5 Independent Contractors. The relationship between the parties is that of independent
contractors. This Agreement will not establish any relationship of partnership, joint venture,
employment, franchise or agency between them. Neither party will have the power to bind the other
without the other party’s prior written consent.

11.6 Governing Law. This Agreement will be governed by and construed in accordance with the laws
of the Province of Ontario and the laws of Canada applicable therein, without reference to the
conflict of laws provisions or principles. The parties agree that any Dispute shall be dealt with
in accordance with Schedule D. The United Nations Convention on Contracts for the International
Sale of Goods does not apply to this Agreement.

11.7 Media. The parties shall consult with each other before issuing any press release or making
any other public announcement with respect to this Agreement or the transactions contemplated
hereby and, except as required by any applicable law or regulatory requirement, neither of them
shall issue any such press release or make any such public announcement without the prior written
consent of the other party, which consent shall not be unreasonably withheld or delayed.

11.8 Force Majeure. Except as expressly provided otherwise in this Agreement, neither party will
be liable for any failure or delay in its performance under this Agreement due to any cause beyond
its reasonable control that could not have been avoided by the exercise of reasonable foresight
provided that the party affected by such failure or delay gives the other party prompt written
notice of the cause, and uses reasonable commercial efforts to correct such failure or delay within
a reasonable period of time (not to exceed 30 days).

[The remainder of this page has intentionally been left blank.]

			
	 
	 	 
	License Agreement — CMS Software
	 	Confidential

 

6

 

IN WITNESS WHEREOF THE PARTIES hereto have executed this Agreement as of the Effective Date:

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	HearUSA, INC.	 	 	 	HELIX HEARING CARE OF AMERICA CORP.	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	By:

	 	 	 	 	 	 	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 
	 

	 	Name:
	 	 	 	 	 	 	 	Name:	 	 	 	 
	 

	 	 	 	 	 	 	 	 	 	 	 	 

	 	 
	 

	 	Title:
	 	 	 	 	 	 	 	Title:	 	 	 	 
	 

	 	 	 	 	 	 	 	 	 	 	 	 

	 	 

[Signature page to the License Agreement]

			
	 
	 	 
	License Agreement — CMS Software
	 	Confidential

 

7

 

SCHEDULE A

GLOSSARY

In this Agreement, the following words and phrases have the meanings set out below:

“Affiliate” means a legal entity that: (a) owns and controls a party, directly or indirectly, or
(b) is owned and controlled, directly or indirectly, by a party, or (c) is directly or indirectly
under common ownership and control with a party.

“Agreement” means the sections and schedules of this Software License Agreement as amended from
time to time, and such other documents as are expressly incorporated by reference in this Software
License Agreement.

“Business Day” means Monday to Friday inclusive, other than a day that is observed as a statutory
or civic holiday in the Province of Ontario.

“Confidential Information” has the meaning set out in Schedule C.

“Dispute” has the meaning set out in Schedule D.

“Documentation” means all documents (regardless of how embodied) that are related to or that are
reasonably required to enable Licensee to use or to obtain the benefit of the Software or Services
including specifications.

“Effective Date” means the date of this Agreement set out at the start of this Agreement.

“Enhancements” means improvements, refinements, upgrades or other modifications to the Software
that add new functionality or features to the Software without being an Update. For clarity,
Enhancements are a subset of the Software.

“Fees” is defined in Section 3.1.

“Harmful Code” is defined in Section 7.2.

“Intellectual Property Rights” means all the intellectual property, industrial and other
proprietary rights, protected or protectable, under the laws of the United States, Canada, any
other country, or any political subdivision thereof, including, without limitation: (i) all trade
names, trade dress, trade-marks, service marks, logos, brand names and other identifiers; (ii)
copyrights, moral rights (including rights of attribution and rights of integrity); (iii) all trade
secrets, inventions, discoveries, devices, processes, designs, techniques, ideas, know how and
other confidential or proprietary information, whether or not reduced to practice; (iv) all
domestic and foreign patents and the registrations, applications, renewals, extensions and
continuations (in whole or in part) thereof; and (v) all goodwill associated therewith and all
rights and causes of action for infringement, misappropriation, misuse, dilution or unfair trade
practices associated with (i) through (iv) above.

“Laws and Regulations” means any and all applicable federal, state, provincial, or municipal (or
other political subdivisions thereof) laws, by-laws, codes, orders, ordinances, rules, regulations
or statutes and all applicable judicial or administrative judgements and orders and rules of common
law that are in existence on the Effective Date of this Agreement or come into existence during the
duration of this Agreement, all as amended, re-enacted, consolidated or replaced, from time to
time.

“Person”, if the context allows, means any individual, person, estate, trust, firm, partnership or
corporation, government or any agency or ministry of any government, and includes any successor to
any of the foregoing.

“Personal Health Information” means any information that is described as personal health
information in section 4 of PHIPA or any similar Laws and Regulations in effect in any province or
territory of Canada.

“Personal Information” means any personal information which is required to be protected pursuant to
any Laws and Regulations pertaining to the protection of personal information. For clarification,
Personal Information is a subset of Confidential Information.

			
	 
	 	 
	License Agreement — CMS Software
	 	Confidential

 

8

 

“PHIPA” means the Personal Health Information Protection Act, 2004, S.O. 2004, Chapter 3, Schedule
A as amended or replaced from time to time.

“Representatives” means, in the case of Licensee, Licensor or any other Person, any directors,
officers, appointees, employees, agents, consultants or subcontractors, as well as the
subcontractor’s directors, officers, employees, agents, consultants or subcontractors.

“Software” means the items of software, including all code to be supplied by Licensor to Licensee,
as set out in Schedule B. Updates and Enhancements provided to Licensee are deemed to be Software.

“Update” means fixes, patches, improvements, refinements or other modifications to the Software
that address any known problem with the Software and may incidentally improve the functionality of
the Software. For clarity, Updates are a subset of the Software.

“User” means any individual who is identified by Licensee as a User and is: (i) a Representative
of Licensee; or (ii) a Representative of any Licensee service provider who requires the right to
obtain access to and to use one or more items of Software in connection with its provision of
services to Licensee.

			
	 
	 	 
	License Agreement — CMS Software
	 	Confidential

 

9

 

SCHEDULE B

SOFTWARE

The following is intended solely as a description of the features and functionality of the Software
and Documentation. To the extent that there is any inconsistency between this Schedule and any
other portion of the Agreement, the other provision shall take precedence.

1. OBJECT CODE

The following modules form part of the Software and Licensor will provide a copy of each of the
following modules to Licensee in object code form:

	(a)	 	Patient Information Module

The Patient Information module of the Software is a tool for capturing patient information
including primary/secondary addresses, responsible parties, primary/secondary physicians, phone
number, referral sources, contact preferences, Date of Birth, visit outcome, and patient notes.

For a more detailed description of the Patient Information module of the Software, please see the
Documentation.

	(b)	 	Appointment Scheduler Module

The Appointment Scheduler module of the Software is a tool for enabling appointment views (by day
by professional by room) and also capturing professional, appointment type, referral source,
appointment confirmation, 3rd party confirmation, appointment status, 3rd party representation, and
appointment notes.

For a more detailed description of the Appointment Scheduler module of the Software, please see the
Documentation.

	(c)	 	Order Module

The Order module of the Software is a tool for capturing hearing aid options, ear mold, repairs and
ordering information.

For a more detailed description of the Order module of the Software, please see the Documentation.

	(d)	 	Invoice & Returns Module

The Invoice & Returns module of the Software is a tool for capturing and calculating invoices based
on insurance plan benefits and allows a reversal of the invoice process.

For a more detailed description of the Invoice & Returns module of the Software, please see the
Documentation.

	(e)	 	Medical Reporting Module

The Medical Reporting module of the Software is a tool that contains the following information,
functions and features:

	 	(i)	 	Captures the patients’ audiometric history

	 	(ii)	 	Food and Drug Administration (FDA) questions

	 	(iii)	 	Prior hearing aid (HA) history which includes purchases

	 	(iv)	 	Help feature to interpret audiometric data

	 	(v)	 	Audiometric findings including speech testing

	 	(vi)	 	Immittance Testing

	 	(vii)	 	Summary of findings and recommendations

	 	(viii)	 	Data can feed into a separate marketing database (Not included)

	 	(ix)	 	Produces a medical consultation form

	 	(x)	 	Auditory brainstem response/electronystagmography (ABR/ENG) interpretation and reporting

For a more detailed description of the Medical Reporting module of the Software, please see the
Documentation.

			
	 
	 	 
	License Agreement — CMS Software
	 	Confidential

 

10

 

	(f)	 	Physician Referral Module

The Physician Referral module of the Software is a tool for capturing primary and specialty
physician information as well as alternate locations.

For a more detailed description of the Physician Referral module of the Software, please see the
Documentation.

	(g)	 	Operational Reporting Module

The Operational Reporting module of the Software is a tool that contains built-in reports that
allow center to manage appointment scheduling, patient, daily operations.

For a more detailed description of the Operational Reporting module of the Software, please see the
Documentation.

	(h)	 	Daily Transaction Module

The Daily Transaction module of the Software is a tool for allowing centers to summarize daily
financial transactions.

For a more detailed description of the Daily Transaction module of the Software, please see the
Documentation.

	(i)	 	Call-Center Capable Interface Module

The Call-Center Capable Interface module of the Software is a tool that contains a built-in ability
that allows a scaled down version of the Software for call-center appointment scheduling.

For a more detailed description of the Call-Center Capable Interface module of the Software, please
see the Documentation.

	(k)	 	Data Mining/Marketing Abilities Module

The Data Mining/Marketing Abilities module of the Software is a tool for enabling Users to capture,
sort and search information contained in the other modules of the Software.

For a more detailed description of the Data Mining/Marketing Abilities module of the Software,
please see the Documentation.

	(l)	 	Price Quoting System Module

The Price Quoting System module of the Software is a tool for allowing professionals to quote and
specify pricing before order creation.

For a more detailed description of the Price Quoting System module of the Software, please see the
Documentation.

	(m)	 	Insurance & Member Information Module

The Insurance & Member Information module of the Software is a tool for capturing patients’ and
members’ primary and secondary insurance information.

For a more detailed description of the Insurance & Member Information module of the Software,
please see the Documentation.

	(n)	 	Insurance Plan Entry Module

The Insurance Plan Entry module of the Software is a tool for allowing Users to capture
unlisted/non-covered insurance plans and patient and member information.

For a more detailed description of the Insurance Plan Entry module of the Software, please see the
Documentation.

			
	 
	 	 
	License Agreement — CMS Software
	 	Confidential

 

11

 

	(o)	 	Plan/Benefit Lookup Module

The Plan/Benefit Lookup module of the Software is a tool for linking to a repository of plan
information including detailed descriptions and benefits (Sample plan will be provided).

For a more detailed description of the Plan/Benefit Lookup module of the Software, please see the
Documentation.

	(p)	 	Report Catalogue Module.

The Report Catalogue module of the Software is a resource for creating various reports. For a more
detailed description of the Report Catalogue module of the Software, please see the Documentation.

2. DOCUMENTATION

Licensor will provide Documentation to Licensee, including without limitation, the following items:

1. The document entitled “Helix Hearing Care Centre CMS and Helix Procedures” (the “Procedures
Document”), a copy of which is attached as Exhibit A to this Schedule B. For purposes of clarity,
the Procedures Document is attached hereto for purposes of describing the functionality of the
Software. Licensee is not required to follow the procedures set out in the Procedures Document.

2. The one page schematic diagram which describes how all of the modules interact with the
Software.

			
	 
	 	 
	License Agreement — CMS Software
	 	Confidential

 

12

 

EXHIBIT A TO SCHEDULE B

HELIX HEARING CARE CENTRE CMS AND HELIX PROCEDURES

Attached is a copy of the document entitled “Helix Hearing Care Centre CMS and Helix Procedures”.

			
	 
	 	 
	License Agreement — CMS Software
	 	Confidential

 

13

 

EXHIBIT B TO SCHEDULE B

SCHEMATIC DIAGRAM OF SOFTWARE

Attached is a copy of the one page schematic diagram which describes how all of the modules
interact with the Software.

			
	 
	 	 
	License Agreement — CMS Software
	 	Confidential

 

14

 

SCHEDULE C

CONFIDENTIALITY AND PRIVACY

1. CONFIDENTIALITY

1.1 Definitions and Background.

	 	(a)	 	“Confidential Information” means any and all information and materials, which:
(i) are designated in writing, as confidential at the time of disclosure, or (ii) a
reasonable person, having regard to the circumstances, would regard as confidential,
including Personal Information. For clarity, the Software and Documentation are
Confidential Information.

	 	(b)	 	Both parties recognize that the protection of any Confidential Information
provided or made available by either party or from whom access is otherwise obtained,
is of vital importance to the party who provided it or made it available or from whom
access is otherwise obtained.

	 	(c)	 	Both parties acknowledge that Confidential Information may include Personal
Health Information and that protecting the privacy of the individuals to whom such
information relates is of paramount concern.

	 	(d)	 	“Disclosing Party” means, with respect to any item of Confidential Information,
the party who provides or otherwise makes available such Confidential Information to
the other party, or from whom access to the Confidential Information is otherwise
obtained, either directly or indirectly.

	 	(e)	 	“Recipient” means, with respect to any item of Confidential Information, the
party who receives or otherwise obtains access to such information.

1.2 Exceptions. Confidential Information does not include information which:

	 	(a)	 	is or at any time is made generally available to the public by the Disclosing
Party, but only after it becomes generally available to the public;

	 	(b)	 	is known to the Recipient (as substantiated by cogent and reliable written
evidence in the Recipient’s possession) free of any restrictions at the time of
disclosure;

	 	(c)	 	is independently developed by the Recipient through individuals who have not
had either direct or indirect access to the Confidential Information; and

	 	(d)	 	is rightfully obtained by the Recipient, without any obligation of confidence
of any kind, from a third party who had a right to transfer or disclose it to the
Recipient free of any obligation of confidence.

The above listed exceptions do not apply in the case of Confidential Information that is also
Personal Information.

1.3 Required by Law. The Recipient shall not be liable for disclosure of Confidential Information
if disclosure is required by law, provided that the Recipient, to the extent permitted by
applicable Laws and Regulations, notifies the Disclosing Party of any such requirement as soon as
legally permissible, so that the Disclosing Party may seek a protective order or other relief.

1.4 Ownership. As between the parties, each party is the owner of its Confidential Information,
and except to the extent set out in this Agreement, no interest, licence or other right in or to
its Confidential Information is granted to the other party or implied simply by the disclosure of
the Confidential Information.

			
	 
	 	 
	License Agreement — CMS Software
	 	Confidential

 

15

 

1.5 Warranties. EXCEPT TO THE EXTENT EXPRESSLY SET OUT OTHERWISE IN THIS AGREEMENT:

	 	(a)	 	ALL CONFIDENTIAL INFORMATION PROVIDED BY OR ON BEHALF OF THE DISCLOSING PARTY
IS PROVIDED ON AN “AS IS” BASIS, WITHOUT ANY WARRANTY, REPRESENTATION OR CONDITION OF
ANY KIND.

	 	(b)	 	WITHOUT LIMITING SECTION 1.5(a), EACH PARTY EXPRESSLY EXCLUDES THE FOLLOWING
REPRESENTATIONS, CONDITIONS AND WARRANTIES WITH RESPECT TO ITS CONFIDENTIAL
INFORMATION: ACCURACY, COMPLETENESS OR NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY
RIGHTS OR OTHER RIGHTS OF THIRD PARTIES.

1.6 Recipient’s Obligations. The Recipient will:

	 	(a)	 	keep the Disclosing Party’s Confidential Information confidential and secure;

	 	(b)	 	use the Disclosing Party’s Confidential Information only in accordance with
this Agreement and only for the purpose of fulfilling its obligations and exercising
its rights under this Agreement and will not directly or indirectly disclose, destroy,
exploit or use any Confidential Information of the Disclosing Party for any other
purpose;

	 	(c)	 	use at least the same degree of care to protect the Disclosing Party’s
Confidential Information as the Recipient uses to protect its own confidential
information of a like nature, but in any event shall not use a standard of care that is
less than a reasonable standard of care, taking into account the sensitivity of any
applicable items of Confidential Information;

	 	(d)	 	not disclose the Disclosing Party’s Confidential Information to any person
other than the Recipient’s Representatives who have a need to know it for the purposes
described in paragraph (b) above and who are bound by a written contract to keep
confidential the confidential information of third parties including the Confidential
Information, at least to the same extent as set forth in this Agreement;

	 	(e)	 	not make copies of any of the Disclosing Party’s Confidential Information or
modify it other than as expressly permitted under this Agreement;

	 	(f)	 	not remove any confidentiality, copyright or other proprietary rights notices
from any of the Disclosing Party’s Confidential Information including from any copies
of such Confidential Information;

	 	(g)	 	upon demand, inform the Disclosing Party of the location of the Disclosing
Party’s Confidential Information and the measures that the Recipient has taken to
preserve its confidentiality; and

	 	(h)	 	notify the Disclosing Party immediately upon becoming aware of any unauthorized
copying, disclosure or use of the Disclosing Party’s Confidential Information by the
Recipient or by any Representative or other individual or entity to whom the Recipient
has disclosed Confidential Information pursuant to this Agreement, and make a
commercially reasonable effort to minimize the effect of any such use or disclosure.

1.7 Equitable Relief. Each party acknowledges that the Confidential Information of the other party
is of value to the other party or to its suppliers and that any breach of this Agreement will cause
irreparable injury to the other party or to any third party to whom the other party owes a duty of
confidence, and that any such injury to the other party or to any such third party may be difficult
to calculate and inadequately compensate in damages. Consequently, each party agrees that in
addition to any other remedies that the other party may have, the other party shall be entitled to
seek injunctive and other equitable relief, as a matter of right without proving injury, and any
other remedy for any actual or potential breach of this Agreement.

			
	 
	 	 
	License Agreement — CMS Software
	 	Confidential

 

16

 

1.8 Return of Confidential Information. The Recipient shall, at any time upon request of the
Disclosing Party and upon termination of this Agreement, immediately return the Disclosing Party’s
Confidential Information and all copies thereof in any form whatsoever under the power or control
of Recipient, to the Disclosing Party, provided
that: (a) to the extent that the Recipient is not reasonably able to return any such Confidential
Information, the Recipient may, with the consent of the Disclosing Party, destroy such Confidential
Information and provide the Disclosing Party with a destruction certificate signed by an
appropriate officer of Recipient certifying such destruction; and (b) the Recipient shall be
entitled to retain the Disclosing Party’s Confidential Information if so required by applicable
Laws and Regulations provided that the Recipient continues to comply with the provisions of this
Agreement pertaining to the protection of Confidential Information which will extend and limit
further uses and disclosures of the Disclosing Party’s Confidential Information to complying with
applicable Laws and Regulations. Without limiting the foregoing, Licensee is not required to
return any Confidential Information for which any right or license is granted to Licensee that
survives the termination of this Agreement.

2. PRIVACY

2.1 Personal Information. The parties shall, at all times, comply with all applicable Laws and
Regulations pertaining to the protection of Personal Information; provided however, that Licensor
shall not be required to modify, update or upgrade the Software or Documentation to comply with any
applicable Laws and Regulations, unless required to do so under a separate agreement.

2.2 Assistance. Each party will promptly provide a reasonable response to any questions posed by
the other party from time to time with respect to compliance with Section 5 of this Agreement and
this Schedule C.

			
	 
	 	 
	License Agreement — CMS Software
	 	Confidential

 

17

 

SCHEDULE D

DISPUTE RESOLUTION

1. DEFINITION OF DISPUTE

“Dispute” means any dispute or controversy between Licensor and Licensee (collectively the
“Parties” and individually a “Party”)) with respect to any matter arising out of or in connection
with this Agreement or otherwise related to this Agreement.

2. GENERAL PRINCIPLES

2.1 Application

Except where expressly excluded from the provisions of this Schedule D, all Disputes shall be
resolved by employing the procedures provided for in this Schedule D.

2.2 Injunctive Relief

For clarification, the provisions of this Schedule D shall not limit or restrict the right of
either Party to seek injunctive relief or to bring any action in any court of law with respect to
any dispute, controversy or claim relating to the improper use or misappropriation of Intellectual
Property Rights or breach of confidentiality or breach of privacy.

2.3 Suspension

Subject to the terms of this Agreement, unless requested or otherwise agreed by the other Party in
writing to do so, neither Party shall stop or suspend its performance under this Agreement pending
the resolution of any Dispute.

2.4 Early Resolution

All Disputes that may arise with respect to any matter governed by this Agreement shall to the
fullest extent possible be resolved collectively by the Parties’ Representatives, or any person
designated by any of them to deal with any category of Dispute.

2.5 Third Parties

The Parties shall cooperate to facilitate the participation of any Person that either Party
reasonably believes can contribute to the resolution of any Dispute.

3. RESOLUTION

3.1 Escalation Process to Resolve a Dispute

First Level of Dispute Resolution — If the Parties’ Representatives are unable to resolve a Dispute
within 10 Business Days, then the Dispute shall be referred to the President (or substantial
equivalent) of each party for resolution (each an “Executive”). The Executives shall make all
reasonable efforts to resolve the Dispute within 20 Business Days of its referral. Each Party
shall ensure that its Executive has the necessary authority to resolve that Dispute on behalf of
that Party.

3.2 Arbitration

	 	(a)	 	If the time periods set out in Section 3.1 of this Schedule D applicable to any
Dispute expire without that Dispute being resolved, either Party may upon Notice to the
other Party, initiate arbitration of the Dispute in accordance with the Rules of the
American Arbitration Association (or its successor) in effect at the date of
commencement of such arbitration to the extent that the provisions of such rules are
not inconsistent with the provisions of this Agreement (the “Rules”).

			
	 
	 	 
	License Agreement — CMS Software
	 	Confidential

 

18

 

	 	(b)	 	If the arbitrator fails to render a decision within 30 days following the final
hearing of the arbitration or any extension of time thereto granted with the written
consent of both Parties, either Party may terminate the appointment of the arbitrator
and a new arbitrator shall be appointed in accordance with these provisions.

	 	(c)	 	The arbitration shall:

	 	(i)	 	be before a single arbitrator appointed in accordance
with the Rules;

	 	(ii)	 	take place in Buffalo, New York at a time, date and place
specified by the arbitrator unless otherwise agreed in writing by Licensee
and Licensor; and

	 	(iii)	 	be final and binding and may be enforced in the same
manner as a judgment or order to the same effect, and no appeal shall lie
therefrom except on questions of law or the jurisdiction of the arbitration.

	 	(d)	 	The arbitrator:

	 	(i)	 	shall not be interested financially in this Agreement or
in either Party’s business;

	 	(ii)	 	shall not be employed by either Party or employed by a
person engaged by either Party;

	 	(iii)	 	shall be required to make his award as soon as possible,
and if at all practicable, within 10 days after the conclusion of the
arbitration hearing;

	 	(iv)	 	may appoint independent experts and any other person to
assist him or her in the hearing of the arbitration;

	 	(v)	 	may determine all questions of law and jurisdiction
including questions as to whether the dispute is arbitrable;

	 	(vi)	 	may determine any question of fact including questions of
good faith, dishonesty or fraud arising in the Arbitration;

	 	(vii)	 	may order any Party to furnish such further details of
that Party’s case, as to fact or law, as it may require;

	 	(viii)	 	may require or permit the Parties to give evidence under oath or solemn
affirmation;

	 	(ix)	 	may order the Parties or either of them to make interim
payments towards the costs of the Arbitration;

	 	(x)	 	shall have the right to grant permanent and interim
damages or injunctive relief; and

	 	(xi)	 	shall have the discretion to award costs including
reasonable legal fees, interest and costs of the arbitration; provided that
the Arbitrator shall not have the right to award any punitive or other
damages specifically excluded by this Agreement.

	 	(e)	 	Unless the Parties shall at any time otherwise agree in writing, the arbitrator
shall have the power, on the application of either of the Parties or of its own motion
(but in either case only after hearing or receiving any representations from the
Parties concerned that it determines in its discretion to be appropriate):

	 	(i)	 	to allow other parties to be joined in the Arbitration
with their express consent, and make a single final award determining all
disputes between them;

			
	 
	 	 
	License Agreement — CMS Software
	 	Confidential

 

19

 

	 	(ii)	 	to allow any Party, upon such terms (as to costs and
otherwise) as it shall determine, to amend its claim, defence, reply,
counter-claim or defence to counter-claim;

	 	(iii)	 	to extend or abbreviate any time limits provided by
these Rules or by its directions;

	 	(iv)	 	to direct the Parties to exchange written statements,
whether or not verified by oath or affirmation, of the evidence of
witnesses, and direct which of the makers of such statements are to attend
before it for oral examinations;

	 	(v)	 	to determine what witnesses (if any) are to attend before
it, and the order and manner (including cross-examination) in which, and by
whom, they are to be orally examined;

	 	(vi)	 	to conduct such further or other inquiries as may appear
to it to be necessary or expedient;

	 	(vii)	 	to order the Parties to make any property or thing
available for its inspection or inspection by another Party and inspect it
in their presence;

	 	(viii)	 	to order the Parties to produce to it, and to each other for inspection,
and to supply copies of, any documents or classes of documents in their
respective possession, control or power that it determines to be relevant;

	 	(ix)	 	to order the preservation or storage of any property or
thing under the control of any of the Parties relevant to the Dispute before
it; and

	 	(x)	 	to make interim orders for security for costs for any
Party’s own costs, and to secure all or part of any amount in dispute in the
Arbitration.

	 	(f)	 	Each Party shall:

	 	(i)	 	cooperate with the arbitrator;

	 	(ii)	 	provide the arbitrator with all information in its
possession or under its control necessary or relevant to the matter being
determined;

	 	(iii)	 	use its best efforts to cause any arbitration hearing
that may be held hereunder to be:

	 	(A)	 	started as soon as practicable, and not later
than 60 days of when the arbitrator is appointed; and

	 	(B)	 	completed as soon as practicable, and if
possible, within one day.

	 	(g)	 	Disputes involving more than two parties shall be settled by one arbitration,
as determined by the arbitration procedures adopted in this clause.

	 	(h)	 	Where by this clause any Dispute is to be referred to arbitration, the making
of a final award shall be a condition precedent to any right of action by either Party
against the other.

	 	(i)	 	Judgment upon an award, including any interim award, rendered by the arbitrator
may be entered in any Court having jurisdiction thereof.

	 	(j)	 	The arbitrator’s fee shall be equally shared by the Parties. The fees of any
independent experts and any other persons appointed to assist the arbitrator shall be
shared equally by the Parties.

			
	 
	 	 
	License Agreement — CMS Software
	 	Confidential

 

20

 

3.3 Confidentiality

The existence of any Dispute being resolved under this Schedule D and any steps or proceedings
taken by the Parties in connection therewith shall be deemed to be Confidential Information of the
Parties, except to the extent that disclosure of such information is required by Laws and
Regulations or is necessary in connection with proceedings instituted in a court of competent
jurisdiction as permitted in this Agreement.

			
	 
	 	 
	License Agreement — CMS Software
	 	Confidential

 

21

 

IN WITNESS WHEREOF THE PARTIES hereto have executed this Agreement as of the Effective Date:

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	HearUSA, INC.	 	 	 	HELIX HEARING CARE OF AMERICA CORP.	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Signature:	 	/s/ Stephen J. Hansbrough	 	 	 	Signature:	 	/s/ Stephen J. Hansbrough	 	 
	 	 	 	 	 	 	 	 	 	 	 
	 

	 	Name:
	 	Stephen J. Hansbrough
	 	 	 	 	 	Name:
	 	Stephen J. Hansbrough	 	 
	 

	 	Title:
	 	Chairman and CEO
	 	 	 	 	 	Title:
	 	Chairman and CEO	 	 

[Signature page to License Agreement]

			
	 
	 	 
	License Agreement — CMS Software
	 	Confidential

 

22Exhibit 10.4

Exhibit 10.4

HEARUSA, INC.

AMENDED AND RESTATED

2007 INCENTIVE COMPENSATION PLAN
 
 RECITALS

WHEREAS, HearUSA, Inc. desires to encourage high levels of performance by those individuals
who are key to the success of the Company, to attract new individuals who are highly motivated and
who will contribute to the success of the Company and to encourage such individuals to remain as
Directors, officers and/or employees of the Company and its subsidiaries by increasing their
proprietary interest in the Company’s growth and success;

WHEREAS, the Plan was originally adopted by the Board of Directors and subsequently approved
by the shareholders on June 11, 2007;

WHEREAS, pursuant to the authority granted to it under section 9.8 hereof, on February 25,
2008, the Compensation Committee approved an amendment to this Plan to permit the Compensation
Committee to exercise its discretion with regard to establishing post-termination option exercise
periods under section 9.5;

WHEREAS, on February 23, 2009, subject to approval of the shareholders of the Company, the
Board of Directors approved amendments to this Plan to increase the number of shares of common
stock available for awards under the plan from 2,500,000 to 4,500,000; to increase the maximum
number of shares that may be covered by grant(s) to any one person during a year from 250,000 to
750,000; and to revise the types of performance criteria that may be the basis for a
performance-based award under the Plan.

NOW, THEREFORE, the Company hereby sets forth this HearUSA, Inc. Amended and Restated 2007
Incentive Compensation Plan to read as follows:

ARTICLE 1

PURPOSE OF THE PLAN

1.1. Purpose. The purpose of the Plan is to assist the Company in attracting and retaining
selected individuals to serve as Directors, officers and employees of the Company or any of its
subsidiaries or affiliates who will contribute to the Company’s success and to achieve long-term
objectives which will inure to the benefit of all shareholders of the Company through the
additional incentive inherent in the ownership of the Company’s common stock.

ARTICLE 2

DEFINITIONS

The following terms shall have the meanings indicated.

 

 

 

2.1. “Award” means Options, Stock Appreciation Rights, Restricted Stock Awards and Restricted
Stock Units.

2.2. “Board” means the board of directors of the Company.

2.3. “Cause” means conviction of a felony involving moral turpitude or the failure to
satisfactorily perform assigned duties after notice to cure has been given.

2.4 “Change of Control” means a “Change in the Ownership of the Company”, a “Change in
Effective Control of the Company”, or a “Change in the Ownership of a Substantial Portion of the
Assets of the Company”, all as defined below. To qualify as a “Change in Control”, the occurrence
of the event must be objectively determinable and any requirement that any other person, such as a
plan administrator or board of directors compensation committee, certify the occurrence of a Change
in Control must be strictly ministerial and not involve any discretionary authority.

A “Change in the Ownership of the Company” occurs on the date that any one person, or more than one
person acting as a group acquires ownership of stock of the Company that, together with stock held
by such person or group, constitutes more than 50 percent of the total fair market value or total
voting power of the stock of the Company. However, if any one person, or more than one person
acting as a group, is considered to own more than 50 percent of the total fair market value or
total voting power of the stock of the Company, the acquisition of additional stock by the same
person or persons is not considered to cause a “Change in the Ownership of the Company”. An
increase in the percentage of stock owned by any one person, or persons acting as a group, as a
result of a transaction in which the Company acquires its stock in exchange for property will be
treated as an acquisition of stock for purposes of this section. This definition applies only when
there is a transfer of stock of the Company (or issuance of stock of the Company) and stock in the
Company remains outstanding after the transaction. Persons will not be considered to be acting as a
group solely because they purchase or own stock of the same corporation at the same time, or as a
result of the same public offering. However, persons will be considered to be acting as a group if
they are owners of a corporation that enters into a merger, consolidation, purchase or acquisition
of stock, or similar business transaction with the Company. If a person, including an entity, owns
stock in both corporations that enter into a merger, consolidation, purchase or acquisition of
stock, or similar transaction, such shareholder is considered to be acting as a group with other
shareholders in a corporation prior to the transaction giving rise to the change and not with
respect to the ownership interest in the other corporation.

A “Change in the Effective Control of the Company” occurs only on the date that either—

(1) Any one person, or more than one person acting as a group, acquires (or has
acquired during the 12-month period ending on the date of the most recent acquisition by
such person or persons) ownership of stock of the Company possessing 35 percent or more of the total voting power of the stock of the Company; or

 

2

 

(2) A majority of members of the Company’s board of directors is replaced during
any 12-month period by directors whose appointment or election is not endorsed by a
majority of the members of the Company’s board of directors prior to the date of the
appointment or election.

Persons will not be considered to be acting as a group solely because they purchase or own
stock of the same corporation at the same time, or as a result of the same public offering.
However, persons will be considered to be acting as a group if they are owners of a
corporation that enters into a merger, consolidation, purchase or acquisition of stock, or
similar business transaction with the Company. If a person, including an entity, owns
stock in both corporations that enter into a merger, consolidation, purchase or acquisition
of stock, or similar transaction, such shareholder is considered to be acting as a group
with other shareholders in a corporation only with respect to the ownership in that
corporation prior to the transaction giving rise to the change and not with respect to the
ownership interest in the other corporation.

A “Change in the Ownership of a Substantial Portion of the Assets of the Company” occurs on the
date that any one person, or more than one person acting as a group, acquires (or has acquired
during the 12-month period ending on the date of the most recent acquisition by such person or
persons) assets from the Company that have a total gross fair market value equal to or more than 40
percent of the total gross fair market value of all of the assets of the Company immediately prior
to such acquisition or acquisitions. For this purpose, gross fair market value means the value of
the assets of the Company, or the value of the assets being disposed of, determined without regard
to any liabilities associated with such assets. Persons will not be considered to be acting as a
group solely because they purchase assets of the same corporation at the same time. However,
persons will be considered to be acting as a group if they are owners of a corporation that enters
into a merger, consolidation, purchase or acquisition of assets, or similar business transaction
with the corporation. If a person, including an entity shareholder, owns stock in both
corporations that enter into a merger, consolidation, purchase or acquisition of assets, or similar
transaction, such shareholder is considered to be acting as a group with other shareholders in a
corporation only to the extent of the ownership in that corporation prior to the transaction giving
rise to the change and not with respect to the ownership interest in the other corporation.

2.5. “Closing Price” means the closing price per Share on the American Stock Exchange or
other exchange on which Shares are traded.

2.6. “Code” means the Internal Revenue Code of 1986, as amended.

2.7. “Committee” means the compensation committee of the Board.

 

3

 

2.8. “Company” means HearUSA, Inc., a Delaware corporation.

2.9. “Director” means a member of the Board.

2.10. “Disability” means total and permanent disability within the meaning of Section 22(e)(3)
of the Code, which, as of the date hereof, means being unable to engage in any substantial gainful
activity by reason of any medically determinable physical or mental impairment which can be
expected to result in death or which has lasted or can be expected to last for a continuous period
of no less than 12 months.

2.11. “Exchange Act” means the Securities Exchange Act of 1934, as amended.

2.12. “Grant Limitation” means the maximum number of Shares with respect to which Awards may
be granted to any Participant during any calendar year as set forth in Section 3.4.

2.13. “Holder” means the holder of a Stock Appreciation Right.

2.14. “Incentive Stock Option” means an Option which qualifies as an incentive stock option
under Section 422 of the Code.

2.15. “Issue” means all descendants, whether natural or adopted, of a Holder, an Optionee or a
Permitted Transferee.

2.16. “Non Employee Director” means a non-employee director within the meaning of Rule 16b-3
promulgated under the Exchange Act.

2.17. “Nonqualified Stock Option” means an Option which is not an Incentive Stock Option.

2.18. “Option” means an Incentive Stock Option and a Nonqualified Stock Option granted
pursuant to Article 5.

2.19. “Optionee” means the recipient of an Option.

2.20. “Outside Director” means an outside director within the meaning of Section 162(m) of the
Code.

2.21. “Participant” means a person who has received an Award or to whom an Award has been
transferred.

2.22. “Permitted Assignee” means (i) the spouse, parent, issue, spouse of issue, or issue of
spouse, of a Holder or an Optionee, (ii) a trust for the benefit of one or more persons described
in clause (i) or for the benefit of a Holder or Optionee, as the case may be, or (iii) an entity in
which a Holder, Optionee or a person described in clauses (i) or (ii) is a beneficial owner.

 

4

 

2.23. “Plan” means this HearUSA, Inc. Amended and Restated 2007 Incentive Compensation Plan.

2.24. “Restricted Shares” means restricted Shares issued pursuant to Article 7.

2.25. “Restricted Stock Agreement” means a restricted stock agreement granted pursuant to
Article 7.

2.26. “Restricted Stock Award” means a restricted stock award granted pursuant to Article 7.

2.27. “Restricted Stock Unit” means a restricted stock unit granted pursuant to Article 8.

2.28. “Restricted Stock Unit Agreement” means a restricted stock unit agreement described in
Article 8.

2.29. “Share” means a share of common stock of the Company.

2.30. “Share Limitation” means the aggregate number of Shares authorized for Awards as
described in Section 3.1.

2.31. “Stock Appreciation Right” means a stock appreciation right granted pursuant to Article
6.

2.32. “Stock Option Agreement” means a stock option agreement described in Article 5.

2.33. “Tax Election” means a written election of a Holder or an Optionee, or a Permitted
Assignee, to have Shares withheld to satisfy withholding taxes as described in Section 10.1.

ARTICLE 3

SHARES SUBJECT TO AWARDS

3.1 Number of Shares. Subject to the adjustment provisions of Section 9.9, the Share
Limitation shall be 4,500,000 Shares. No Options to purchase fractional Shares shall be granted or
issued under the Plan. For purposes of this Section 3.1, the Shares that shall be counted toward
the Share Limitation shall include all Shares:

(1) issued or issuable pursuant to Options that have been or may be exercised;

(2) issued or issuable pursuant to Stock Appreciation Rights;

 

5

 

(3) issued as, or subject to issuance as Restricted Stock Awards; and

(4) issued as, or subject to issuance as Restricted Stock Units.

3.2 Shares Subject to Terminated Awards. The Shares covered by any unexercised portions of
terminated Options granted under Article 5, Shares forfeited as provided in Section 7.2(a) and
Shares subject to any Awards which are otherwise surrendered by the Participant without receiving
any payment or other benefit with respect thereto may again be subject to new Awards under the
Plan. In the event the purchase price of an Option is paid in whole or in part through the
delivery of Shares, the number of Shares issuable in connection with the exercise of the Option
shall not again be available for the grant of Awards under the Plan. Shares subject to Options, or
portions thereof, which have been surrendered in connection with the exercise of share appreciation
rights shall not again be available for the grant of Awards under the Plan.

3.3 Character of Shares. Shares delivered under the Plan may be authorized and unissued
Shares, treasury Shares acquired by the Company, or both.

3.4 Limitations on Grants to Individual Participant. Subject to the adjustment provisions of
Section 9.9 the Grant Limitation shall be 750,000 Shares. If an Award is canceled, the Shares with
respect to such canceled Award shall continue to be counted toward the Grant Limitation for the
year granted.

ARTICLE 4

ELIGIBILITY AND ADMINISTRATION

4.1 Awards to Employees and Directors. (a) Participants who are eligible to receive Awards
shall consist of such key employees and Directors of the Company or any of its subsidiaries or
affiliates as the Committee shall select from time to time. The Committee’s designation of a
Participant in any year shall not require the Committee to designate such person to receive Awards
or grants in any other year. The designation of a Participant to receive Awards or grants under
one portion of the Plan shall not require the Committee to include such Participant under other
portions of the Plan.

(b) No Option which is intended to qualify as an Incentive Stock Option may be granted to any
employee who, at the time of such grant, owns, directly or indirectly (within the meaning of
sections 422(b)(6) and 424(d) of the Code), shares possessing more than ten percent (10%) of the
total combined voting power of all classes of shares of the Company or any of its subsidiaries or
affiliates, unless at the time of such grant, (i) the option price is fixed at not less than 110%
of the Closing Price (as defined below) of the Shares subject to such Option, determined on the
date of the grant, and (ii) the exercise of such Option is prohibited by its terms after the
expiration of five (5) years from the date such Option is granted. Incentive Stock Options may only
be granted to employees of the Company or its subsidiaries.

 

6

 

4.2 Administration. (a) The Plan shall be administered by the Committee. Unless otherwise
determined by the Board, each member of the Committee shall be a Non- Employee Director and an Outside Director. In no event shall the Committee consist of fewer
than two Directors. The Directors may remove from, add members to, or fill vacancies in the
Committee.

Any Award to a member of the Committee shall be on terms consistent with Awards made to other
non-employee Directors who are not members of the Committee, except where the Award is approved or
ratified by the Board (excluding persons who are also members of the Committee).

(b) The Committee is authorized, subject to the provisions of the Plan, to establish such
rules and regulations as it may deem appropriate for the conduct of meetings and proper
administration of the Plan. All actions of the Committee shall be taken by majority vote of its
members. The Committee is also authorized, subject to the provisions of the Plan, to make
provisions in various Awards pertaining to a Change of Control of the Company and to amend or
modify existing Awards; provided, however, that the Committee may not, without first obtaining the
approval of the shareholders of the Company, reprice any outstanding Option then exercisable for a
price above the then current market price of the Shares to provide for a lower exercise price.

(c) Subject to the provisions of the Plan, the Committee shall have authority, in its sole
discretion, to interpret the provisions of the Plan and, subject to the requirements of applicable
law, including Rule 16b-3 of the Exchange Act, to prescribe, amend, and rescind rules and
regulations relating to it as it may deem necessary or advisable. All decisions made by the
Committee pursuant to the provisions of the Plan shall be final, conclusive and binding on all
persons, including the Company, its shareholders, Directors and employees, and Plan participants.

ARTICLE 5

OPTIONS

5.1 Grant of Options. The Committee shall determine, within the limitations of the Plan, the
Directors and employees of the Company and its subsidiaries and affiliates to whom Options are to
be granted under the Plan, the number of Shares that may be purchased under each such Option and
the option price, and shall designate such Options at the time of the grant as either Incentive
Stock Options or Nonqualified Stock Options. An Option is the right to purchase Shares at a
specified price.

All Options granted pursuant to this Article 5 shall be authorized by the Committee and shall
be evidenced in writing by Stock Option Agreements in such form and containing such terms and
conditions as the Committee shall determine which are not inconsistent with the provisions of the
Plan, and, with respect to any Stock Option Agreement granting Options which are intended to
qualify as Incentive Stock Options, are not inconsistent with Section 422 of the Code. Granting of
an Option pursuant to the Plan shall impose no obligation on the Optionee to exercise such option.
Any individual who is granted an Option pursuant to this Article 5 may hold more than one Option at
the same time and may hold both Incentive Stock Options and Nonqualified Stock Options at the same
time. To the extent that any Option does not qualify as an Incentive Stock Option
(whether because of its provisions, the time or manner of its exercise or otherwise) such
Option or the portion thereof which does not so qualify shall constitute a separate Nonqualified
Stock Option.

 

7

 

5.2 Option Price. Subject to Section 4.1(b), the option price per each Share purchasable under
any Option granted pursuant to this Article 5 shall not be less than 100% of the Closing Price of
such Share on the date of the grant of such Option or, if the market was closed on the date in
question, then the closing price on the next trading day immediately following the day in question.
If the Shares are traded on more than one market or exchange, then the Closing Price shall be
determined by reference to the primary market or exchange where the Shares trade.

5.3 Other Provisions. Options granted pursuant to this Article 5 shall be made in accordance
with the terms and provision of Article 9 and any other applicable terms and provisions of the
Plan.

ARTICLE 6

STOCK APPRECIATION RIGHTS

6.1 Grant and Exercise. Stock Appreciation Rights may be granted in conjunction with all or
part of any Option granted under the Plan provided such rights are granted at the time of the grant
of such Option. A Stock Appreciation Right is the right to receive cash or Shares, as provided in
this Article 6. It may be the right to receive cash or Shares, in lieu of the purchase of Shares
under a related Option or it may be a free standing stock appreciation right unrelated to any
Option. A Stock Appreciation Right or applicable portion thereof shall terminate and no longer be
exercisable upon the termination or exercise of a related Option, and a Stock Appreciation Right
granted with respect to less than the full number of Shares covered by a related Option shall not
be reduced until, and then only to the extent that, the exercise or termination of the related
Option exceeds the number of Shares not covered by the share appreciation right. A Stock
Appreciation Right may be exercised by the Holder, in accordance with Section 6.2 of this Article
6, by giving written notice thereof to the Company and surrendering the applicable portion of the
related Option. Upon giving such notice and surrender, the Holder shall be entitled to receive an
amount determined in the manner prescribed in Section 6.2 of this Article 6. Options which have
been so surrendered, in whole or in part, shall no longer be exercisable to the extent the related
share appreciation rights have been exercised

6.2 Terms and Conditions. Stock Appreciation Rights shall be subject to such terms and
conditions, not inconsistent with the provisions of the Plan, as shall be determined from time to
time by the Committee, including the following:

(a) Stock Appreciation Rights shall be exercisable only at such time or times and to
the extent that the Options to which they relate shall be exercisable in accordance with
the provisions of the Plan or, with respect to free-standing Stock Appreciation Rights,
only at such time or times as provided in the grant agreement for such Stock Appreciation
Right as determined by the Committee.

 

8

 

(b) Upon the exercise of a Stock Appreciation Right, a Holder shall be entitled to
receive up to, but no more than, an amount in cash or whole Shares equal to the excess of
the then Fair Market Value of one Share over the option price per Share specified in the
related Option (or the grant date value of the Stock Appreciation Right in the case of a
free-standing Stock Appreciation Right) multiplied by the number of Shares in respect of
which the Stock Appreciation Right shall have been exercised. The Holder shall specify in
his written notice of exercise, whether payment shall be made in cash or in whole Shares
unless otherwise provided in the Stock Appreciation Right grant agreement. Each share
appreciation right may be exercised only at the time and so long as a related Option, if
any, would be exercisable or as otherwise permitted by applicable law or the terms of the
grant agreement (in the case of a free-standing Stock Appreciation Right).

(c) Upon the exercise of a Stock Appreciation Right, the Option or part thereof to
which such share appreciation right is related shall be deemed to have been exercised for
the purpose of the limitation of the number of Shares to be issued under the Plan, as set
forth in Section 3.1.

(d) With respect to Stock Appreciation Rights granted in connection with an Option
that is intended to be an Incentive Stock Option, the following shall apply:

(i) No Stock Appreciation Right shall be transferable by a Holder otherwise
than by will or by the laws of descent and distribution, and Stock Appreciation
Rights shall be exercisable, during the Holder’s lifetime, only by the Holder.

(ii) Stock Appreciation Rights granted in connection with an Option may be
exercised only when the Fair Market Value of the Shares subject to the Option
exceeds the option price at which Shares can be acquired pursuant to the Option.

ARTICLE 7

RESTRICTED STOCK AWARDS

7.1 Restricted Stock Awards. (a) In General. A grant of Shares made pursuant to this Article
7 is referred to as a Restricted Stock Award. The Committee may grant to any Participant an amount
of Shares in such manner, and subject to such terms and conditions relating to vesting,
forfeitability and restrictions on delivery and transfer (whether based on performance standards,
periods of service or otherwise) as the Committee shall establish. The terms of any Restricted
Stock Award granted under the Plan shall be set forth in a written Restricted Stock Agreement which
shall contain provisions determined by the Committee and not inconsistent with the Plan. The
provisions of Restricted Stock Awards need not be the same for each Participant receiving such
Awards. Any Restricted Stock Award that is intended to qualify as performance based compensation
under Section 162(m) of the Code shall have as its performance criteria, one or more of the
criteria set forth in Section 9.10 and shall preclude discretion to increase the amount payable upon the attainment
of the performance goals.

 

9

 

(b) Issuance of Restricted Shares. As soon as practicable after the date of grant of a
Restricted Stock Award by the Committee, the Company shall cause to be transferred on the books of
the Company, Shares registered in the name of the Company, as nominee for the Participant,
evidencing the Restricted Shares covered by the Award, but subject to forfeiture to the Company
retroactive to the date of grant, if a Restricted Stock Agreement delivered to the Participant by
the Company with respect to the Restricted Shares covered by the Award is not duly executed by the
Participant and timely returned to the Company. All Restricted Shares covered by Awards under this
Article 7 shall be subject to the restrictions, terms and conditions contained in the Plan and the
Restricted Stock Agreement entered into by and between the Company and the Participant. Until the
lapse or release of all restrictions applicable to an Award of Restricted Shares, the share
certificates representing such Restricted Shares shall be held in custody by the Company or its
designee.

(c) Shareholder Rights. Beginning on the date of grant of the Restricted Stock Award and
subject to execution of the Restricted Stock Agreement as provided in Sections 7.1(a) and (b), at
the discretion of the Committee, the Participant may become a shareholder of the Company with
respect to all Shares subject to the Restricted Stock Agreement and may have all of the rights of a
shareholder, including, but not limited to, the right to vote such Shares and the right to receive
distributions made with respect to such Shares; provided, however, that any Shares distributed as a
dividend or otherwise with respect to any Restricted Shares as to which the restrictions have not
yet lapsed shall be subject to the same restrictions as such Restricted Shares and shall be
represented by book entry and held as prescribed in Section 7.1(b).

(d) Restriction on Transferability. None of the Restricted Shares may be assigned or
transferred (other than by will or the laws of descent and distribution), pledged or sold prior to
lapse or release of the restrictions applicable thereto.

(e) Delivery of Shares Upon Release of Restrictions. Upon expiration or earlier termination of
the forfeiture period without a forfeiture and the satisfaction of or release from any other
conditions prescribed by the Committee, the restrictions applicable to the Restricted Shares shall
lapse. As promptly as administratively feasible thereafter, subject to the requirements of Section
10.1, the Company shall deliver to the Participant or, in case of the Participant’s death, to the
Participant’s beneficiary, one or more stock certificates for the appropriate number of Shares,
free of all such restrictions, except for any restrictions that may be imposed by law.

7.2 Terms of Restricted Shares.

(a) Forfeiture of Restricted Shares. Subject to Section 7.2(b), all Restricted Shares shall
be forfeited and returned to the Company and all rights of the Participant with respect to such
Restricted Shares shall terminate unless the Participant continues in the service of the Company as
an employee until the expiration of the forfeiture period for such Restricted Shares and satisfies
any and all other conditions set forth in the Restricted Stock Agreement. The Committee in its
sole discretion, shall determine the forfeiture period (which may, but need not, lapse in installments) and any other terms and
conditions applicable with respect to any Restricted Stock Award.

 

10

 

(b) Waiver of Forfeiture Period. Notwithstanding anything contained in this Article 7 to the
contrary, the Committee may, in its sole discretion, waive the forfeiture period and any other
conditions set forth in any Restricted Stock Agreement under appropriate circumstances (including
the death, Disability or retirement of the Participant or a material change in circumstances
arising after the date of an Award) and subject to such terms and conditions (including forfeiture
of a proportionate number of the Restricted Shares) as the Committee shall deem appropriate.

ARTICLE 8

RESTRICTED STOCK UNITS

8.1. Award of Restricted Stock Units. Subject to the terms of this Article 8, a Restricted
Stock Unit entitles a Participant to receive cash or one Share for each Restricted Stock Unit at
the end of a specified restricted period to the extent provided by the Award. The Committee may
Award to any Participant an amount of Restricted Stock Units in such manner, and subject to such
terms and conditions relating to vesting, forfeitability, restrictions on delivery and transfer
(whether based on performance standards, periods of service or otherwise), and such other
provisions as the Committee shall establish. The terms of an Award of a Restricted Stock Unit
under the Plan shall be set forth in a written Restricted Stock Unit Agreement which shall contain
the Restricted Period(s), the number of Restricted Stock Units granted, and such other provisions
determined by the Committee and not inconsistent with the Plan. The provisions of Restricted Stock
Units need not be the same for each Participant receiving such Awards. Any Restricted Stock Unit
award that is intended to qualify as performance based compensation under Section 162(m) of the
Code shall have as its performance criteria, one or more of the criteria set for the in Section
9.10 and shall preclude discretion to increase the amount payable upon the attainment of the
performance goals.

8.2 Termination of Employment. Except to the extent the Committee specifies otherwise, any
Restricted Stock Unit which is not earned and vested by the end of the restricted period specified
in the Award shall be forfeited. If a Participant’s date of termination (or, in the case of a
non-employee Director, separation from service) occurs prior to the end of such restricted period,
the Committee, in its sole discretion, may determine that the Participant will be entitled to
settlement of all or any portion of the Restricted Stock Units as to which he or she would
otherwise be eligible, and may accelerate the determination of the value and settlement of such
Restricted Stock Units or make such other adjustments as the Committee, in its sole discretion,
deems desirable.

8.3 Restricted Stock Units. Except to the extent the Plan or the Committee specifies
otherwise, Restricted Stock Units represent an unfunded and unsecured obligation of the Company.
During any period in which Restricted Stock Units are outstanding and have not been settled in
Shares, the Participant shall not have the rights of a stockholder, but, in the discretion of the
Committee, may be granted the right to receive a payment from the Company in lieu of a dividend as
set forth in the Restricted Stock Unit Agreement in an

 

11

 

amount equal to any cash dividends that might be paid during the restricted period specified
in the Award. With respect to any grant contemplated by the foregoing sentence, no such grant
shall be made to a Participant unless it complies with the requirements of Section 409A of the Code
(unless otherwise agreed to by the Committee and the Participant). Until a Restricted Stock Unit
is settled, the number of Shares represented by a Restricted Stock Unit shall be subject to
adjustment pursuant to Section 9.9.

ARTICLE 9

GENERALLY APPLICABLE PROVISIONS

9.1 Option Period. Subject to Section 4.1(b), the period for which an Option is exercisable
shall not exceed ten (10) years from the date such Option is granted. After the Option is granted,
the option period may not be reduced.

9.2 Fair Market Value. If the Shares are listed or admitted to trading on a securities
exchange registered under the Exchange Act, the Fair Market Value of a Share as of a specified date
shall mean the Closing Price for the day on which Fair Market Value is being determined (or if
there was no reported sale on such date, on the next succeeding date on which any reported sale
occurred) reported on the principal securities exchange on which the Shares are listed or admitted
to trading. If the Shares are not listed or admitted to trading on any such exchange but are
traded in the over-the-counter market or are traded on any similar system then in use, the Fair
Market Value of a Share shall be the Closing Price for the day on which the Fair Market Value is
being determined (or if there was no reported sale on such date, on the next succeeding date on
which any reported sale occurred) reported on such system. If the Shares are not listed or
admitted to trading on any such exchange and are not traded in the over-the-counter market or
traded on any similar system then in use, but are quoted on the National Association of Securities
Dealers, Inc. Automated Quotations System or any similar system then in use, the Fair Market Value
of a Share shall be the closing high bid and low asked quotations on such system for the Shares on
the date in question. If the Shares are not publicly traded, Fair Market Value shall be determined
by the Committee in its sole discretion using appropriate criteria. An Option shall be considered
granted on the date the Committee acts to grant the Option or such later date as the Committee
shall specify.

9.3 Exercise of Options. Options granted under the Plan shall be exercised by the Optionee
thereof (or by his or her executors, administrators, guardian or legal representative, or by a
Permitted Assignee, as provided in Sections 9.6 and 9.7 hereof) as to all or part of the Shares
covered thereby, by the giving of written notice of exercise to the Company, specifying the number
of Shares to be purchased, accompanied by payment of the full purchase price for the Shares being
purchased. Full payment of such purchase price shall be made within five (5) business days
following the date of exercise and shall be made (i) in cash or by certified check or bank check,
(ii) with the consent of Committee, by tendering previously acquired Shares (valued at Fair Market
Value, as determined by the Committee as of the date of tender), or (iii) with the consent of the
Committee, any combination of (i) and (ii). In connection with a tender of previously acquired
Shares pursuant to clause (ii) above, the Committee, in its sole discretion, may permit the
Optionee to constructively exchange Shares already owned by the Optionee in lieu of actually
tendering such Shares to the

 

12

 

Company, provided that adequate documentation concerning the ownership of the Shares to be
constructively tendered is furnished in form satisfactory to the Committee. The notice of
exercise, accompanied by such payment, shall be delivered to the Company at its principal business
office or such other office as the Committee may from time to time direct, and shall be in such
form, containing such further provisions consistent with the provisions of the Plan, as the
Committee may from time to time prescribe. In no event may any Option granted hereunder be
exercised for a fraction of a Share. The Company shall effect the transfer of Shares purchased
pursuant to an Option as soon as practicable, and, within a reasonable time thereafter, such
transfer shall be evidenced on the books of the Company. No person exercising an Option shall have
any of the rights of a holder of Shares subject to an Option until certificates for such Shares
shall have been issued following the exercise of such Option. No adjustment shall be made for cash
dividends or other rights for which the record date is prior to the date of such issuance. To the
extent permitted in a Stock Option Agreement in effect prior to the adoption of the Plan or
pursuant to a stock appreciation right an Optionee may receive a net cash payment (in cancellation
of the Option or Stock Appreciation Right), subject to the terms and conditions set forth in such
Stock Option Agreement or stock appreciation right.

9.4 Transferability. No Option that is intended to qualify as an Incentive Stock Option shall
be assignable or transferable by the Optionee, other than by will or the laws of descent and
distribution, and such Option may be exercised during the life of the Optionee only by the Optionee
or his guardian or legal representative. Nonqualified Stock Options and any Stock Appreciation
Rights granted in tandem therewith are transferable (together and not separately) by the Optionee
or Holder, as the case may be, to any Permitted Assignee; provided, however, that such Permitted
Assignee shall be bound by all of the terms and conditions of the Plan and shall execute an
agreement satisfactory to the Company evidencing such obligation; provided further, however that
any transfer by an Optionee or Holder who is not then a Director of the Company to any Permitted
Assignee shall be subject to the prior consent of the Committee; and provided further, however,
that such Optionee or Holder shall remain bound by the terms and conditions of the Plan. The
Company shall cooperate with an Optionee’s Permitted Assignee and the Company’s transfer agent in
effectuating any transfer permitted pursuant to this Section 9.4.

9.5 Termination of Employment. In the event of the termination of employment of an Optionee
or the separation from service of a Director (who is an Optionee) for any reason (other than death
or Disability as provided below), any Option(s) held by such Optionee (or its Permitted Assignee)
under the Plan and not previously exercised or expired shall be deemed canceled and terminated on
the day of such termination or separation, unless the Committee decides, in its sole discretion, to
extend the term of the Option, provided, however, that in no instance may the term of the Option,
as so extended, exceed the maximum term set forth in Section 4.1(b)(ii) or 9.1 above.
Notwithstanding the foregoing, in the event of the separation from service of a non-employee
Director (who is an Optionee) by reason of death, disability or under conditions satisfactory to
both the Director and the Company, any nonqualified stock options held by such Director (or its
Permitted Assignee) under the Plan and not previously exercised or expired shall be exercisable for
a period not to exceed five (5) years after the date of such separation, provided, however, that in
no instance may the term of the Option, as so extended, exceed the maximum term set forth in
Sections 4.1(b)(ii) or 9.1 above.

 

13

 

9.6 Death. In the event an Optionee (other than a non-employee Director) dies while employed
by the Company or any of its subsidiaries or affiliates any Option(s) held by such Optionee (or its
Permitted Assignee) and not previously expired or exercised shall, to the extent exercisable on the
date of death, be exercisable by the estate of such Optionee or by any person who acquired such
Option by bequest or inheritance, or by the Permitted Assignee at any time within one year after
the death of the Optionee, unless earlier terminated pursuant to its terms, provided, however, that
if the term of such Option would expire by its terms within six months after the Optionee’s death,
the term of such Option shall be extended until six months after the Optionee’s death, provided
further, however, that in no instance may the term of the Option, as so extended, exceed the
maximum term set forth in Section 4.1(b)(ii) or 9.1 above.

9.7 Disability. In the event of the termination of employment of an Optionee (other than a
non-employee Director) due to Disability, the Optionee, or his guardian or legal representative, or
a Permitted Assignee shall have the unqualified right to exercise any Option(s) which have not been
previously exercised or expired and which the Optionee was eligible to exercise as of the first
date of Disability (as determined by the Committee), at any time within one (1) year after such
termination, unless earlier terminated pursuant to its terms; provided, however, that if the term
of such Option would expire by its terms within six months after such termination, the term of such
Option may be extended until six months after such termination at the discretion of the Committee;
provided further, however, that in no instance may the term of the Option, as so extended, exceed
the maximum term set forth in Section 4.1(b)(ii) or 9.1 above.

9.8 Amendment and Modification of the Plan. The Committee may, from time to time, alter,
amend, suspend or terminate the Plan as it shall deem advisable, subject to any requirement for
shareholder approval imposed by applicable law or any rule of any stock exchange or quotation
system on which Shares are listed or quoted; provided that such Committee may not amend the Plan,
without the approval of the Company’s shareholders, to increase the number of Shares that may be
the subject of awards under the Plan (except for adjustments pursuant to Section 9.9 hereof). In
addition, no amendments to, or termination of, the Plan shall in any way impair the rights of an
Optionee or a Participant (or a Permitted Assignee thereof) under any Award previously granted
without such Optionee’s or Participant’s consent.

9.9 Adjustments. In the event that the Committee shall determine that any dividend, or other
similar distribution (whether in the form of cash, Shares, other securities, or other property),
recapitalization, stock split, reverse stock split, reorganization, merger, consolidation,
split-up, spin-off, combination, repurchase, or exchange of Shares or other securities, the
issuance of warrants or other rights to purchase Shares or other securities, or other similar
corporate transaction or event affects the Shares with respect to which Awards have been or may be
issued under the Plan, such that an adjustment is determined by the Committee to be appropriate in
order to prevent dilution or enlargement of the benefits or potential benefits intended to be made
available under the Plan, then the Committee shall, in such manner as the Committee deems
equitable, adjust any or all of (i) the number and type of Shares that thereafter may be made the
subject of Awards, (ii) the number and type of Shares subject to outstanding Awards, and (iii) the
grant or exercise price with respect to any Award, or, if deemed appropriate, make provision for a
cash payment to the holder of any

 

14

 

outstanding Award; provided, in each case, that with respect to Incentive Stock Options, no
such adjustment shall be authorized to the extent that such adjustment would cause such options to
violate Section 422(b) of the Code or any successor provision (unless otherwise agreed by the
Committee and the holder of such Option); and provided further, that the number of Shares subject
to any Award denominated in Shares shall always be a whole number. In the event of any
reorganization, merger, consolidation, split-up, spin-off, or other business combination involving
the Company, the Committee or the Board may cause any Award outstanding as of the effective date of
any such transaction to be canceled in consideration of a cash payment or alternate Award made to
the holder of such canceled Award equal in value to the fair market value of such canceled Award.
The determination of fair market value shall be made by the Committee or the Board, as the case may
be, in their sole discretion. With respect to each adjustment contemplated by this Section 9.9, no
such adjustment shall be authorized to the extent that such adjustment would cause an Award to
violate the provisions of Section 409A of the Code (unless otherwise agreed by the Committee and
the holder of such Award).

9.10. Performance Based Compensation. Unless and until the Committee proposes for shareholder
vote and the shareholders approve a change in the performance criteria set forth in this Section
9.10, the performance criteria upon which the payment under, or vesting of, an Award intended to
qualify as performance based compensation under Section 162(m) of the Code, is based shall consist
of one or any combination of two or more of the following: (a) revenues; (b) net earnings or net
income (before or after taxes); (c) funds from operations; (d) earnings per share; (e) net sales
growth; (f) net operating profit; (g) return measures (including return on assets, capital,
invested capital, equity or sales); (h) cash flow (including operating cash flow, free cash flow,
and cash flow return on capital); (i) earnings before or after taxes, interest depreciation and/or
amortization; (j) gross or operating margins; (k) productivity ratios; (l) Share price (including
growth measures and total shareholder return); and (m) achievement of operational or strategic
objectives determined by the Board of Directors. Any of the foregoing may be used to measure the
performance of the Company, subsidiary and/or affiliate as a whole or any business unit thereof.

ARTICLE 10

MISCELLANEOUS

10.1 Tax Withholding. All payments or distributions made pursuant to the Plan to an Optionee
or Participant (or a Permitted Assignee thereof) shall be net of any applicable federal, state and
local withholding taxes arising as a result of the grant of any Award, exercise of an Option or
stock appreciation rights or any other event occurring pursuant to the Plan. The Company shall
have the right to withhold from such Optionee or Participant (or a Permitted Assignee thereof) such
withholding taxes as may be required by law, or to otherwise require the Optionee or Participant
(or a Permitted Assignee thereof) to pay such withholding taxes. If the Optionee or Participant
(or a Permitted Assignee thereof) shall fail to make such tax payments as are required, the Company
or its subsidiaries or affiliates shall, to the extent permitted by law, have the right to deduct
any such taxes from any payment of

 

15

 

any kind otherwise due to such Optionee or Participant or to take such other action as may be
necessary to satisfy such withholding obligations. In satisfaction of the requirement to pay
withholding taxes, the Optionee or Participant (or Permitted Assignee) may make a Tax Election,
which may be accepted or rejected in the discretion of the Committee.

10.2 Right of Discharge Reserved. Nothing in the Plan nor the grant of an Award hereunder
shall confer upon any employee, Director or other individual the right to continue in the
employment or service of the Company or any subsidiary or affiliate of the Company or affect any
right that the Company or any subsidiary or affiliate of the Company may have to terminate the
employment or service of (or to demote or to exclude from future Options under the Plan) any such
employee, Director or other individual at any time for any reason. Except as specifically provided
by the Committee, the Company shall not be liable for the loss of existing or potential profit from
an Award granted in the event of termination of an employment or other relationship even if the
termination is in violation of an obligation of the Company or any subsidiary or affiliate of the
Company to the employee or Director.

10.3 Nature of Payments. All Awards made pursuant to the Plan are in consideration of
services performed for the Company or any subsidiary or affiliate of the Company. Any income or
gain realized pursuant to Awards under the Plan and any share appreciation rights constitutes a
special incentive payment to the Optionee, Participant or Holder and shall not be taken into
account, to the extent permissible under applicable law, as compensation for purposes of any of the
employee benefit plans of the Company or any subsidiary or affiliate of the Company except as may
be determined by the Committee or by the Directors or directors of the applicable subsidiary or
affiliate of the Company.

10.4 Severability. If any provision of the Plan shall be held unlawful or otherwise invalid
or unenforceable in whole or in part, such unlawfulness, invalidity or unenforceability shall not
affect any other provision of the Plan or part thereof, each of which remain in full force and
effect. If the making of any payment or the provision of any other benefit required under the Plan
shall be held unlawful or otherwise invalid or unenforceable, such unlawfulness, invalidity or
unenforceability shall not prevent any other payment or benefit from being made or provided under
the Plan, and if the making of any payment in full or the provision of any other benefit required
under the Plan in full would be unlawful or otherwise invalid or unenforceable, then such
unlawfulness, invalidity or unenforceability shall not prevent such payment or benefit from being
made or provided in part, to the extent that it would not be unlawful, invalid or unenforceable,
and the maximum payment or benefit that would not be unlawful, invalid or unenforceable shall be
made or provided under the Plan.

10.5 Gender and Number. In order to shorten and to improve the understandability of the Plan
document by eliminating the repeated usage of such phrases as “his or her” and any masculine
terminology herein shall also include the feminine, and the definition of any term herein in the
singular shall also include the plural except when otherwise indicated by the context.

10.6 Governing Law. The Plan and all determinations made and actions taken thereunder, shall
be governed by the laws of the State of Delaware, without regard to the principles of conflicts of
law which might otherwise apply.

 

16

 

10.7 Termination of Plan. The Plan shall be effective on the date of the approval of the Plan
by the holders of a majority of the shares entitled to vote thereon, provided such approval is
obtained within 12 months after the date of adoption of the Plan by the Board. Awards may be
granted under the Plan at any time and from time to time on or prior to April 27, 2017, on which
date the Plan will expire except as to Awards and related share appreciation rights then
outstanding under the Plan. Such outstanding Awards and stock appreciation rights shall remain in
effect until they have been exercised or terminated, or have expired.

10.8 Captions. The captions in the Plan are for convenience of reference only, and are not
intended to narrow, limit or affect the substance or interpretation of the provisions contained
herein.

 

17

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00162-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00162-of-00352.parquet"}]]